H.C. Wainwright analyst Edward White reiterated a Buy rating on Inhibikase Therapeutics (IKT – Research Report) today and set a price target of $5.00. The company’s shares opened today at $0.65.
White covers the Healthcare sector, focusing on stocks such as TG Therapeutics, SAB Biotherapeutics, and Lumos Pharma. According to TipRanks, White has an average return of -8.9% and a 30.24% success rate on recommended stocks.
Inhibikase Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $5.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $1.21 and a one-year low of $0.44. Currently, Inhibikase Therapeutics has an average volume of 317.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inhibikase Therapeutics Inc is a clinical stage pharmaceutical company developing therapeutics for Parkinson’s Diseases and related disorders inside and outside the brain. Its pipeline product, IkT-148009, targets underlying disease mechanisms to reverse the course of Parkinson’s disease and the GI complications of Parkinson’s disease.
Read More on IKT:
- Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
- Inhibikase Therapeutics provides update on Parkinson’s trials
- Inhibikase Therapeutics initiated with a Buy at H.C. Wainwright
- Inhibikase Therapeutics Reports Full Year 2022 Financial Results and Highlights Recent Period Activity
- Inhibikase Therapeutics, Inc. (IKT) Q4 Earnings Cheat Sheet
